Pfizer has agreed to buy weight-loss drug startup Metsera in a deal that could be worth more than $10 billion, besting rival Novo Nordisk following a heated bidding war

Core Insights - Pfizer has successfully outbid Novo Nordisk in a competitive bidding process for a weight-loss startup, indicating a strategic move to enhance its portfolio in the obesity treatment market [1] Company Summary - Pfizer's victory in the bidding war highlights its aggressive strategy to expand into the weight-loss sector, which is becoming increasingly lucrative due to rising obesity rates globally [1] - Novo Nordisk, a key player in diabetes and obesity treatments, faced unexpected competition, suggesting a shift in the competitive landscape of the pharmaceutical industry [1] Industry Summary - The weight-loss market is experiencing heightened interest from major pharmaceutical companies, driven by increasing consumer demand and the potential for significant revenue growth [1] - The bidding war reflects a broader trend of consolidation and competition within the healthcare sector, particularly in areas related to chronic disease management [1]